Patents by Inventor George D. Hartman

George D. Hartman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
    Publication number: 20210252014
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 19, 2021
    Inventors: Scott Kuduk, George D. Hartman
  • DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS
    Publication number: 20210188849
    Abstract: Provided herein are compounds of formula (I) and (V) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 24, 2021
    Inventors: Scott Kuduk, George D. Hartman
  • Oxadiazepinone derivatives and methods of treating hepatitis B infections
    Patent number: 10987359
    Abstract: Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 27, 2021
    Assignee: Novira Therapeutics, Inc.
    Inventors: Scott Kuduk, George D. Hartman
  • Diazepinone derivatives and their use in the treatment of hepatitis B infections
    Patent number: 10975077
    Abstract: Provided herein are compounds of formula (I) and (V) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 13, 2021
    Assignee: Novira Therapeutics, Inc.
    Inventors: Scott Kuduk, George D. Hartman
  • OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
    Publication number: 20200197408
    Abstract: Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: June 29, 2017
    Publication date: June 25, 2020
    Inventors: Scott Kuduk, George D. Hartman
  • DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS
    Publication number: 20200181144
    Abstract: Provided herein are compounds of formula (I) and (V) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: June 29, 2017
    Publication date: June 11, 2020
    Inventors: Scott Kuduk, George D. Hartman
  • Derivatives And Methods Of Treating Hepatitis B Infections
    Publication number: 20200181142
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: December 3, 2019
    Publication date: June 11, 2020
    Inventors: George D. Hartman, Scott Kuduk
  • Combination therapy for treatment of HBV infections
    Patent number: 10632112
    Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: April 28, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10556904
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 11, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10544141
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: January 28, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Azocane and azonane derivatives and methods of treating hepatitis B infections
    Patent number: 10537580
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 21, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Derivatives and methods of treating hepatitis B infections
    Patent number: 10538519
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: January 21, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Azepane derivatives and methods of treating hepatitis B infections
    Patent number: 10392349
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 27, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • METABOLIC RESTRICTION IN CELL-BASED ASSAYS
    Publication number: 20190234940
    Abstract: Provided are methods and assays used in the screening and identification of agents in assays that use metabolically active cells.
    Type: Application
    Filed: October 2, 2017
    Publication date: August 1, 2019
    Inventors: Man Iu LAM, Christine Lisa ESPIRITU, Scott KUDUK, George D. HARTMAN
  • Azepane derivatives and methods of treating hepatitis B infections
    Patent number: 10364228
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: July 30, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS
    Publication number: 20190209541
    Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
    Type: Application
    Filed: December 28, 2018
    Publication date: July 11, 2019
    Inventor: George D. Hartman
  • DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
    Publication number: 20190194191
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: George D. Hartman, Scott Kuduk
  • DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
    Publication number: 20190077800
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: August 31, 2018
    Publication date: March 14, 2019
    Inventors: George D. Hartman, Scott Kuduk
  • Combination therapy for treatment of HBV infections
    Patent number: 10213420
    Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: February 26, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Hepatitis B antiviral agents
    Patent number: 10196376
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 5, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Osvaldo A. Flores